Berlin, Germany

Rolalnd Ederdt

This inventor holds 1 USPTO granted patent. Top assignee: Schering Aktiengesellschaft. Active years: 1993.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rolalnd Ederdt. Retrieved from https://idiyas.com/inventor/rolalnd-ederdt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1993

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Rolalnd Ederdt

Introduction

Rolalnd Ederdt is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceuticals, particularly through his work on leukotriene-B4 derivatives. His innovative approach has led to advancements in medical treatments.

Latest Patents

Ederdt holds one patent titled "Leukotriene-B4 derivatives, process for their production and their use." This patent showcases his expertise in developing compounds that have potential therapeutic applications.

Career Highlights

Ederdt is associated with Schering Aktiengesellschaft, a prominent pharmaceutical company. His work at Schering has allowed him to focus on research and development in the field of biochemistry and pharmacology.

Collaborations

Ederdt has collaborated with esteemed colleagues such as Josef Heindl and Werner Skuballa. These partnerships have fostered a productive environment for innovation and discovery.

Conclusion

Rolalnd Ederdt's contributions to the field of pharmaceuticals through his patent and collaborations highlight his role as an influential inventor. His work continues to impact medical science positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…